Ensuring Breath Test Results Match Clinical Impressions

According to Insight Partners, “Small Intestinal Bacterial Overgrowth: A Case-Based Review’ published in the Journal of Patient-Centered Research and Reviews (JPCRR) in November 2015, 30-85% of adult patients with IBS are likely to develop SIBO.

Similarly, recent data published by the American College of Gastroenterology found that ~78% of IBS patients are living with SIBO. The prevalence of IBS and SIBO will likely grow significantly in the near future, leading to the increasing diagnosis and eventual market growth.

In 2020, the breath testing segment held the largest share of the market and is expected to grow at the fastest rate during the coming years. The growth is attributed due to its advantages, such as non-invasive, patient-friendly, simplicity, and low-cost.

Yahoo Finance suggests:

• The 2021 SIBO market was estimated at $140M US
• The 2028 SIBO market is estimated to be $194M US
• The 2030 SIBO market is estimated to be $205M US, with an estimated CAGR of 4.3% from 2022 to 2030

Join us on October 17rd at 11am PST as Gary Stapleton, MBA, founder of Aerodiagnostics speaks on matching breath testing results to clinical impressions.

‍